Auto Injector Market Is Estimated To Grow At CAGR Of 16.60%, 2022-2030

Grow more relationships

Puno, Nov. 24, 2022 (GLOBE NEWSWIRE) — According to a new market research report titled “Auto injector market by product type (disposable auto-injectors, reusable auto-injectors), by disease indication (rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, other), and by end-user (hospitals, home care, other) – Global Outlook and Forecast 2022-2030″ published by Growth Plus Reports, the auto-injector market is expected to grow at a pace CAGR or 16.60% from 2021 to be achieved $191.21 billion by 2030.

Download the sample PDF brochure or Auto injector market:


Increasing demand for targeted therapies and self-administration is the primary driver driving the global auto-injector market. Furthermore, the rising incidence of anaphylaxis, migraines, and chronic diseases like diabetes, rheumatoid arthritis, and multiple sclerosis is also a major driver of the global auto-injector market. Auto-injectors have many benefits, including higher quality and dosage effectiveness, less needle phobia, fewer needlestick injuries and accidents, and improved dosing accuracy. The increase in biologics research and development, as well as the increasing approval of biologics and biosimilars, is facilitating the growth of the auto-injector market. The adoption of cutting-edge technologies, expiration of biological patents and increased investment by market leaders to produce cost-effective and reusable injectors are expected to drive market growth.

The global Autoinjectors market has been analyzed from three perspectives: product type, disease indication, end user, and region.

Extract from ‘Segmentation by product type’

Based on the product type, the global auto injector market is split into two parts

  • Single use

  • Reusable automatic injectors

Disposable auto-injectors will hold the largest market share in 2021. The large share of disposable auto-injectors is mainly attributed to their ease of use. They have a built-in syringe, which eliminates the need to manually load the syringe and thus increases the safety of the device. Biopharmaceutical companies are investing in advanced technologies to improve disposable auto-injectors. For example, in March 2022, Ipsen announced that it is investing in a new state-of-the-art electronic auto-injector for Somatuline, Autogel/Somatuline Depot (lanreotide), to bring further innovation to the class to improve the administration and injection experience for patients. This device will be made in collaboration with Phillips-Medisize.

Excerpts from “Segmentation by disease indication”

Based on disease indications, the global auto-injector market is segmented into

  • Rheumatoid arthritis

  • Multiple sclerosis

  • Diabetes

  • Anaphylaxis

  • Other therapies

The anaphylaxis segment dominates the market with the largest market share in 2021. Diabetes is another major application area for auto-injectors. The segment is growing due to increased demand for insulin auto-injectors. According to the International Diabetes Federation, type 1 diabetes affects approximately 10% of the diabetic population, with approximately 1.2 million children and adolescents affected. Additionally, the demand for self-administered insulin in home care is also driving growth in the segment.

Excerpts from “Segmentation by Region”

Based on the region, the global auto injectors market has been categorized into

  • North America

  • Europe

  • Asia Pacific

  • The rest of the world

North America dominated the global auto-injector market in 2021. Europe has the second largest market for auto-injectors. The large market share can be attributed to the growing prevalence of anaphylaxis and chronic diseases such as diabetes, rheumatoid arthritis and multiple sclerosis. According to the European Academy of Allergy and Clinical Immunology (EAACI) more than 150 million people in Europe suffer from chronic allergic diseases. In the UK, around 20% of the population suffers from allergies. According to the MRC Asthma UK Center in Allergic Mechanisms of Asthma, around 20-30 deaths are caused by allergies in the UK.

Excerpts from “Competitive Landscape”

Some prominent players operating in the global auto injector market are

  • Mylan NV

  • Abbey Inc.

  • Eli Lilly and company

  • Amgen Inc.

  • Becton, Dickinson and company

  • Ypsomed Holding AG

  • Johnson & Johnson

  • Teva Pharmaceutical Industries Ltd

  • Pfizer Inc.

  • Merck Kgaa

  • Owen Mumford

  • Halozyme Therapeutics

  • Glaxosmithkline Plc

  • Biogen Inc.

  • Sanofì SA

  • Scandinavian Health Ltd.

Inquire before purchasing this research report:

Table of contents


    1. Market ecosystem

    2. Chronology under review

      1. Historic Years – 2020

      2. Base year – 2021

      3. Planned years: 2022 to 2030

    3. Currency used in the report


    1. Research approach

    2. Data collection methodology

    3. Data origin

      1. Secondary sources

      2. Primary sources

    4. Approach to market estimation

      1. Bottom up

      2. Upside down

    5. Market prediction model

    6. Limitations and assumptions


    1. Current market trends (COVID-19 perspective)

    2. Key Players and Competitive Positioning (2021)


    1. Drivers

    2. Restrictions/Challenges

    3. Chance


    1. Disposable auto-injectors

    2. Reusable automatic injectors

      1. pre-compiled

      2. Empty


    1. Rheumatoid arthritis

    2. Multiple sclerosis

    3. Diabetes

    4. Anaphylaxis

    5. Other therapies


    1. hospitals

    2. Home care

    3. Others (Outpatient Surgical Centers, Day Care, etc.)

Table of Contents Continue…

Scope of the report:

Ratio attribute


Market size value in 2021

48 billion US dollars

Revenue forecast in 2030

191.21 billion US dollars

Rate of growth

CAGR of 16.60% from 2022 to 2030

Base year for the estimate


Forecast period


Segments covered

Product type, disease indication, end user and region.

regional scope

North America, Europe, Asia Pacific and Rest of the World (ROW)


  • Powered with hours of free analysis and expert interviews with every report

  • Comprehensive quantitative and qualitative insights at the segment and sub-segment level

  • Covid 19 impacts trends and perspectives

  • Granular insights at global/regional/country level

  • In-depth insights into market dynamics (drivers, constraints, opportunities) and the business environment

  • Global coverage of the competitive landscape

  • Winning imperatives

  • Comprehensive coverage of the “strategic developments” recorded by the main market players


  • Distributor landscape assessment

  • conduct assessment

  • Pricing intelligence

  • Evaluation of the customer base

  • Analysis of investments and initiatives

  • “Company profile” or key players

Buy Premium Copy quickly or Auto injector market Report:

Who we are

Growth Plus Reports is part of GRG Health, a global health knowledge services company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth+ portfolio of services draws on our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable and game-changing solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO magazine as “Most Innovative Healthcare Market Research Firm 2020.

CONTACT: Manan Sethi Director, Market Insights Email: Phone no: +91 96545 76783 Web:

Leave a Comment

%d bloggers like this: